Cara Therapeutics, Inc.

DB:69C0 Stock Report

Market Cap: €21.1m

Cara Therapeutics Management

Management criteria checks 2/4

Cara Therapeutics' CEO is Chris Posner, appointed in Nov 2021, has a tenure of 3.17 years. total yearly compensation is $2.92M, comprised of 24.9% salary and 75.1% bonuses, including company stock and options. directly owns 0.22% of the company’s shares, worth €46.18K. The average tenure of the management team and the board of directors is 3.2 years and 5.5 years respectively.

Key information

Chris Posner

Chief executive officer

US$2.9m

Total compensation

CEO salary percentage24.9%
CEO tenure3.2yrs
CEO ownership0.2%
Management average tenure3.2yrs
Board average tenure5.5yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Chris Posner's remuneration changed compared to Cara Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$96m

Jun 30 2024n/an/a

-US$111m

Mar 31 2024n/an/a

-US$123m

Dec 31 2023US$3mUS$728k

-US$119m

Sep 30 2023n/an/a

-US$117m

Jun 30 2023n/an/a

-US$112m

Mar 31 2023n/an/a

-US$84m

Dec 31 2022US$3mUS$700k

-US$85m

Sep 30 2022n/an/a

-US$89m

Jun 30 2022n/an/a

-US$66m

Mar 31 2022n/an/a

-US$93m

Dec 31 2021US$10mUS$116k

-US$88m

Sep 30 2021n/an/a

US$24m

Jun 30 2021n/an/a

US$8m

Mar 31 2021n/an/a

US$14m

Dec 31 2020US$280kn/a

US$8m

Sep 30 2020n/an/a

-US$99m

Jun 30 2020n/an/a

-US$115m

Mar 31 2020n/an/a

-US$113m

Dec 31 2019US$302kn/a

-US$106m

Sep 30 2019n/an/a

-US$98m

Jun 30 2019n/an/a

-US$85m

Mar 31 2019n/an/a

-US$79m

Dec 31 2018US$494kn/a

-US$74m

Compensation vs Market: Chris's total compensation ($USD2.92M) is above average for companies of similar size in the German market ($USD463.17K).

Compensation vs Earnings: Chris's compensation has increased whilst the company is unprofitable.

CEO

Chris Posner (54 yo)

3.2yrs

Tenure

US$2,922,469

Compensation

Mr. Christopher A. Posner also known as Chris, served as Independent Director of Zevra Therapeutics, Inc. (formerly known as KemPharm, Inc.), since November 2022. He serves as President and Chief Executive...

Leadership Team

NamePositionTenureCompensationOwnership
Christopher Posner
President3.2yrsUS$2.92m0.22%
€ 46.2k
Ryan Maynard
Chief Financial Officer2.3yrsUS$1.24m0.015%
€ 3.1k
Derek Chalmers
Co-Founder & Senior Advisor3.2yrsUS$10.20mno data
Scott Terrillion
Chief Compliance Officer8.2yrsUS$1.59m0.15%
€ 31.3k
Matthew Murphy
Manager of Investor Relationsno datano datano data

3.2yrs

Average Tenure

57.5yo

Average Age

Experienced Management: 69C0's management team is considered experienced (3.2 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Christopher Posner
President6.4yrsUS$2.92m0.22%
€ 46.2k
Martin Vogelbaum
Independent Chairman & Lead Independent Director14.5yrsUS$519.99k0.20%
€ 42.1k
Graeme Milligan
Member of the Scientific Advisory Boardno datano datano data
Stanley Watson
Member of the Scientific Advisory Boardno datano datano data
James Kauer
Member of the Scientific Advisory Boardno datano datano data
Philip Portoghese
Member of the Scientific Advisory Boardno datano datano data
Jeffrey L. Ives
Independent Director10.5yrsUS$272.49k0.087%
€ 18.4k
Helen Boudreau
Independent Director1.4yrsUS$376.01k0%
€ 0
Susan Shiff
Independent Director4.6yrsUS$262.49k0.094%
€ 19.8k
Lisa von Moltke
Independent Director2.2yrsUS$254.99k0.059%
€ 12.4k

5.5yrs

Average Tenure

61.5yo

Average Age

Experienced Board: 69C0's board of directors are considered experienced (5.5 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/09 23:02
End of Day Share Price 2024/12/30 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Cara Therapeutics, Inc. is covered by 15 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jason Matthew GerberryBofA Global Research
Corey DavisCanaccord Genuity
Charles DuncanCantor Fitzgerald & Co.